The proportion of CD8+ cells within the CD3+ population increased in all organs in vivo, ranging from 91.42% in the lung to 96.35% in the tumor, compared to pre-injection TILs (67.85%) (Supplementary Figure S6A). This evidence concerns the gene CD8A and neoplasm.